Search
Harrow Inc
HROWAdd to Watchlist
37.605USD
-0.625-1.63%
Market hours （ET）Quotes delayed by 15 min
1.40BMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-1.63%
5 Days
-8.06%
1 Month
+4.66%
6 Months
+10.15%
Year to Date
-23.26%
1 Year
+54.12%
TradingKey Stock Score of Harrow Inc
Currency: USD Updated: 2026-05-08Key Insights
Harrow Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 48 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 66.71.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Harrow Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Harrow Inc Highlights
StrengthsRisks
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 109.15% year-on-year.
Undervalued
The company’s latest PE is -273.46, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 22.48M shares, decreasing 6.07% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 127.88K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.25.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
66.714
Target Price
+74.51%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Harrow Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Harrow Inc Info
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Ticker SymbolHROW
CompanyHarrow Inc
CEOMullery (Frank)
Websitehttps://www.harrow.com/
Related Instruments
+1.81%
-0.15%
-0.04%
+0.85%
+0.82%
-0.63%
-1.10%
-0.85%
+1.91%
+1.14%
+0.12%
-1.01%
+1.32%
-1.30%
-0.97%
-1.24%
0.00%
-0.45%
+2.45%
-0.65%Popular Instruments
95.478
+3.285 (+3.56%)
292.500
-0.550 (-0.19%)
220.800
+5.600 (+2.60%)
4727.150
+12.870 (+0.27%)
521.570
+41.570 (+8.66%)
1557.990
-4.350 (-0.28%)
804.335
+57.525 (+7.70%)
392.815
-7.985 (-1.99%)
82050.260
+1345.380 (+1.67%)
443.800
+15.450 (+3.61%)
